Introduction
This issue of Oncogene is dedicated to reviews on the topic of 'mRNA translation control in cancer pathogenesis'. The various chapters describe how the detailed knowledge of the molecular mechanisms and the signaling pathways which control mRNA translation and the protein synthetic machinery have identified steps potentially involved in tumorigenesis, in turn pointing at novel 'druggable targets' for cancer therapy (Bader and Vogt, 2004; Clemens, 2004; De Benedetti and Graff, 2004; Fingar and Blenis, 2004; Holland et al., 2004; Mamane et al., 2004; Perrotti and Calabretta, 2004; Rajasekhar and Holland, 2004; Rosenwald, 2004; Schmidt, 2004; Stoneley and Willis, 2004; White, 2004) . Virtually all the reviews focus on the role that deregulated mRNA translation control may play in oncogenesis, describing the work performed in eukaryotic cells and mammalian systems. This is a deliberate decision, as, in the post-genomic era and with the advent of sophisticated technology for the manipulation of the mouse genome, we will be able to deconvolute the complexity of these processes in the mammalian system and hopefully deconstruct their relevance for the pathogenesis of human cancer.
Where are the smoking guns?
No one would argue that deregulated control of the protein synthetic machinery might participate in cancer pathogenesis. After all, cancer-associated morphological changes in the nucleolus were recognized since the end of the 19th century (Pianese, 1896) , Sonenberg and colleagues described in the early 1990s the in vitro transforming ability of eIF4E, a rate-limiting initiation factor of mRNA translation (Lazaris-Karatzas et al., 1990; see also Clemens, 2004; De Benedetti and Graff, 2004) ; Holland et al., 2004; Mamane et al., 2004, all in this issue) and an important proto-oncogene such as c-Myc was found to regulate the cell size, protein synthesis and translation initiation a few years ago (Iritani and Eisenman, 1998; see also Schmidt, 2004) . Nevertheless, until recently, skepticism has permeated the notion that aberrant translational control could be a driving force of the oncogenic process. The hypothesis was probably dismissed by many (where are the smoking guns?), based on correlative observations (e.g. the nucleolar changes) or on in vitro studies (e.g. eIF4e transforming ability in 3T3 cells) and, importantly, because of lack of genetic evidence in support of the fact that deregulation of these processes may causally relate to neoplastic transformation both in human patients and in animal models.
Things have radically changed in the last few years for several reasons:
(i) Human cancer susceptibility syndromes have been attributed to mutations in tumor suppressor genes that control protein synthesis (e.g. TSC1/2 and PTEN; see Bader and Vogt, 2004; Fingar and Blenis, 2004; Holland et al., 2004 , all in this issue) or in tumor suppressor genes that control ribosome biogenesis (e.g. DKC1 and the ribosomal protein S19; see and references therein; .
(ii) the oncogenic role of these genetic events and of deregulated expression of protein translational regulators has now been demonstrated in vivo in animal models (e.g. eIF4E transgenic mice do develop cancer of various histological origins (Ruggero et al., in press ), while Dkc-1 KO mice are tumor prone ). (iii) effective anticancer drugs have been proven to impact on key regulators of the protein synthetic machinery (rapamycin as an mTOR inhibitor: see also Bader and Vogt, 2004; Fingar and Blenis, 2004; Holland et al., 2004 , all in this issue).
Open questions
These recent advances concerning the role of aberrant mRNA translation in tumorigenesis have in turn raised a number of questions concerning how the deregulation in this process could be etiopathogenic. As many specific questions will be addressed in the various review articles of this dedicated issue, here we will synthetically outline the fundamental challenges that will face our research on this topic in the years to come.
Upstream or downstream the ribosome?
Substantial evidence has been accrued in support of the notion that oncogenic signaling pathways (e.g. PI3K-mTOR: upstream the ribosome) may be transduced at the mRNA translation level either by affecting the ribosome function or the activity of initiation factors, as extensively discussed in many review articles of this special issue (Figure 1a ). In this respect, the protein synthetic machinery itself does not need to be misfunctional and can be regarded as the passive recipient of aberrant signaling cues. In a more provocative scenario (downstream the ribosome), the protein synthetic machinery (e.g. the ribosome) would be misfunctional, leading to disease and cancer (Figure 1b) . Support of this hypothesis has been obtained through the identification of mutations and rearrangements in genes encoding proteins known to modulate ribosome biogenesis associated with both cancer susceptibility syndromes (e.g. DKC-1 germline mutations in Dyskeratosis congenita (DC); Figure 1b) or tumors of various histological origins (e.g. somatic chromosomal translocations involving the NPM locus (also known as B23/ nucleophosmin) associated with various hemopoietic malignancies; see Redner et al., 1996 and references therein) . NPM has been in fact implicated in the control of ribosome biogenesis (Savkur and Olson, 1998 and references therein), processes that may be perturbed by the oncogenic fusion proteins, which result from these chromosomal translocations (see, for instance, Piazza et al., 2001) . However, the most compelling example of a 'ribosome disease' is undoubtedly represented by DC, a disease characterized by features of premature aging and increased susceptibility to cancer . Mutations in the DKC1 gene encoding a pseudouridine synthase, which mediates post-transcriptional modification of ribosomal RNA (rRNA) through the site-specific conversion of uridine (U) to pseudouridine (C) have been associated with DC. In yeast and fly, mutations in this gene result in impaired rRNA modifications associated with a reduction in ribosome biogenesis, defects also observed in mammalian cells from hypomorphic Dkc1 mutant (Dkc1m) mice Figure 1 Role of protein translation control in tumorigenesis. (a) In a first scenario, the ribosome is structurally normal, but mRNA translation is abnormal because of aberrant signaling (e.g. sustained mTOR activation), leading to deregulated or excessive mRNA translation. (b) Ribosome-driven tumorigenesis. In a second scenario, a malfunctioning ribosome may directly contribute to cancer pathogenesis by affecting either globally or specifically mRNA translation Aberrant mRNA translation PP Pandolfi . Importantly Dkc1m mice recapitulate, in first generations, the clinical features of DC, indicating that deregulated ribosome function participates in the initiation of DC. In addition, more than 50% of Dkc1 mutant mice develop tumors during their life span, unraveling the critical tumor suppressive role of Dkc1 . Although the 'downstream the ribosome' hypothesis is appealing, it nevertheless remains to be determined how a misfunctional protein synthetic machinery may trigger oncogenesis.
Quality vs quantity
Three hypotheses, not mutually exclusive, can be entertained in rationalizing how aberrant mRNA translation could lead to neoplastic transformation (Figure 2 ). On the one hand, the protein synthetic machinery can be stimulated to translate an excessive amount of proteins, leading to an increase in cell size and resulting in excessive cell division in the absence of functional check points. Indeed, profound effects on cell size have been documented upon both aberrant PI3K signals or deregulated c-Myc activity (see the review articles in this issue). In this scenario, mRNA translation would be affected globally. It remains to be determined whether an excessive cell size is sufficient to lead to inappropriate cell division. To this end, it will be critical to identify the molecular check point(s) that, in mammalian cells, are able to restrain division or to cause programmed death of cells rendered too large because of excessive protein synthesis, as loss of these check points may cooperate with genetic events that lead to excessive protein synthesis. On the other hand, altered ribosome biogenesis or aberrant initiation of translation may lead to specific and oncogenic defects in mRNA translation. In DC, as an example, alterations in rRNA pseudouridylation may affect regions of the ribosome that are important for tRNA and mRNA binding. The reduction in modified uridine residues in the ribosome could in turn result in impaired translation of specific mRNAs that are important for cellular transformation. Genes encoding tumor suppressors such as p27 and p58 have been shown to contain 5 0 internal ribosome entry site (IRES) leader sequences, and translation of these types of mRNAs may be sensitive to alterations in ribosome folding (Ruggero and Pandolfi, 2003 and references therein) . Alternatively, in an even more provocative scenario, a misfunctional ribosome could mistranslate mRNAs into aberrant oncogenic proteins (Figure 2 ).
Do we have the critical players at hand and is the nucleolus the key integration hub?
It is already apparent that the steps for control of mRNA translation and ribosome biogenesis are multiple and highly integrated with the cell cycle control machinery. It is also obvious, however, that we have at hand only a few of the molecules that are implicated in the modulation of these processes. Novel proteins are being discovered that may play a role in the integration of cell cycle control and ribosome biogenesis in the nucleolus (e.g. nucleostemin; Bernardi and Pandolfi (2003) and references therein). The nucleolus itself is being revisited from a cellular site where two distinct and apparently independent functions would take place: (i) ribosome biogenesis; (ii) titration of proteins for cell cycle control and tumor suppression (e.g. the Mdm2 pro-oncogene which is titrated by ARF in the nucleolus to allow the stabilization of the p53 tumor suppressor; Bernardi and , to a subnuclear compartment where these two functions are actively integrated (see, for instance, recent reports in which ARF and NPM/B23 are found to physically and functionally antagonize each other in the nucleolus; Itahana et al., 2003; Bertwistle et al., 2004) . This novel dimension of the nucleolus is still fully unexplored, as it remains to be determined whether other cellular compartments (e.g. the endoplasmic reticulum) could also serve as additional hubs for the integration of mRNA translation and cell cycle/survival control.
Perspectives
In summary, this is an exciting moment where important progresses will be certainly made in determining the molecular basis underlying a number of disorders, Figure 2 Possible outcomes of deregulated control of protein translation in tumorigenesis. Whether the oncogenic event acts upstream the ribosome or it is ribosome intrinsic/specific (e.g. altered ribosome biogenesis caused by DKC-1 inactivation), this may lead to global and/or selective quantitative defects in mRNA translational or in qualitative defects in protein translation (mistranslation) including cancer, caused by aberrant ribosome function and mRNA translation. This will be facilitated by the utilization of novel high-throughput methodologies (see, for instance, Rajasekhar and Holland, 2004, in this issue) . This new knowledge will be also of relevance for the development of novel therapeutic modalities. Many of the steps involved in this control network and in ribosome biogenesis are in fact intrinsically druggable because they rely on enzymatic activities (e.g. mTOR as a kinase; dyskerin as pseudouridine synthase). To this end, it will be of paramount importance to assess genetically in vivo in the mouse the relative significance in cancer pathogenesis of each component in the mRNA translation control network in order to identify such key targets for therapy.
